SECsense Logo

Alnylam Pharmaceuticals 8-K Report: Key Corporate Updates on February 13, 2025

$ALNY
Form 8-K
Filed on: 2025-02-13
Source
Alnylam Pharmaceuticals 8-K Report: Key Corporate Updates on February 13, 2025

From the provided XML section of a financial report, the following key information can be extracted:

  1. Entity Information:
  • Company Name: Alnylam Pharmaceuticals, Inc.
  • State of Incorporation: Delaware (DE)
  • CIK Number: 0001178670
  • IRS Employer Identification Number (EIN): 77-0602661
  • Address: 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142
  • Phone Number: 617-551-8200
  1. Filing Information:
  • Filing Type: 8-K (a report of unscheduled material events or corporate changes)
  • Filing Date: February 13, 2025
  1. Securities Information:
  • Common Stock: Par value of $0.01 per share
  • Ticker Symbol: ALNY
  • Exchange: NASDAQ
  1. Reporting Period:
  • Start Date: February 13, 2025
  • End Date: February 13, 2025

Insights:

  • The filing indicates a significant event or change that requires immediate disclosure under the 8-K form, which is critical for investors and stakeholders.
  • The report was filed on the same day as the reporting period start and end, suggesting timely communication of potentially important information.
  • As a publicly traded entity on NASDAQ, Alnylam Pharmaceuticals is subject to SEC regulations and reporting requirements, which ensures transparency for investors.

This information is vital for analysts and investors to assess the company's current situation, compliance status, and any pertinent developments that may affect the company's stock and overall market performance.